EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 Cardiol Therapeutics Inc.: Exhibit 99.2 - Filed by newsfilecorp.com

June 27, 2024

RE:  Cardiol Therapeutics Inc. - Report of Voting Results

In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, the voting results from Cardiol Therapeutics Inc.'s Annual General Meeting of Shareholders held on June 26, 2024, were as follows:

Item 1: Election of Directors

On a vote by electronic ballot (including votes cast by proxy), the following directors were re-elected for the ensuing year: Chris Waddick, Colin Stott, David Elsley, Dr. Guillermo Torre-Amione, Jennifer Chao, Michael Willner, Peter Pekos, and Teri Loxam.

Nominees Number of
Votes For		 Percentage of
Votes For		 Number of Votes
Withheld		 Percentage of Votes
Withheld
Chris Waddick 17,352,587 96.10% 705,007 3.90%
Colin Stott 17,349,964 96.09% 706,730 3.91%
David Elsley 17,994,588 99.66% 62,106 0.34%
Dr. Guillermo Torre-Amione 17,345,669 96.07% 710,125 3.93%
Jennifer Chao 17,346,733 96.07% 709,961 3.93%
Michael Willner 17,348,726 96.08% 707,968 3.92%
Peter Pekos 17,336,814 96.01% 719,880 3.99%
Teri Loxam 17,348,275 96.08% 708,419 3.92%

Item 2: Appointment of Auditors

On a vote by electronic ballot (including votes cast by proxy), BDO Canada LLP were appointed as auditors of the Corporation until the next annual meeting and the directors of the Corporation were authorized to fix the remuneration to be paid to the auditors.

  Number of
Votes For		 Percentage of
Votes For		 Number of
Votes Withheld		 Percentage of Votes
Withheld
Appointment of Auditors 26,420,071 99.09% 243,265 0.91%

Item 3: Omnibus Equity Incentive Plan

On a vote by electronic ballot (including votes cast by proxy), the number of Class A common shares of the Corporation reserved for issuance and the unallocated Awards under the Corporation's Omnibus Equity Incentive Plan were approved.

  Number of
Votes For		 Percentage of
Votes For		 Number of
Votes Against		 Percentage of Votes
Against
Omnibus Equity Incentive Plan 16,288,760 90.21% 1,767,934 9.79%

CARDIOL THERAPEUTICS INC.

(signed) Chris Waddick

Chris Waddick

Chief Financial Officer and Corporate Secretary